Ivermectin to Treat Cancer - Quick Reference Sheet
evipedia.ai ← Back

Ivermectin to Treat Cancer

Created on 06/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A cheap, long-used anti-parasite medicine that laboratory science suggests might also act against cancer by stressing cancer-cell energy production and blocking growth signals. These findings are reproducible in cells and animals, but benefit in people remains unproven. The most serious danger is using it in place of treatments known to work. (Full Review)

Protocol

Use Only As Adjunct
Never a replacement
Retain standard oncology treatment; an experimental add-on only under medical supervision. No established evidence-based protocol exists.
Dosing
Once-daily, oral, with food
A fatty meal markedly increases absorption. Off-label protocols use higher weight-based doses, often in cycles; trial dosing is set by protocol.
Sourcing
Human-grade only
Never veterinary products. Compounded preparations depend on a reputable, licensed compounder with verifiable quality.
Time to effect
Cancer Outcome
Not established
No reliable time-to-effect is established for any cancer outcome.
Subjective Change
Weeks to months
Uncontrolled reports describe subjective changes over weeks to months, but these cannot be attributed to the drug with confidence.

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Children below standard weight thresholds
  • Significant liver impairment (Child-Pugh Class B–C)
  • Known ABCB1 loss-of-function or compromised blood-brain barrier
  • Anyone for whom it would replace a curative standard therapy
    •
Key Interactions
  • CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice)
  • P-glycoprotein inhibitors (verapamil, cyclosporine, quinidine, amiodarone)
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort)
  • Other CNS depressants (benzodiazepines, sedating GABAergic agents)
  • Warfarin
  • Hepatotoxic co-medications (high-dose mebendazole, fenbendazole, doxycycline, methotrexate, alcohol)
  • Supplements with additive or interacting effects (milk thistle/silymarin, CYP3A4-modulating botanicals, high-fat vehicles)
    •

Risk & Side Effects

  • High: Foregoing or delaying proven cancer treatment; gastrointestinal side effects
    •
  • Medium: Hepatotoxicity (liver injury); neurological effects
    •
  • Low: Visual disturbances and ocular effects; skin reactions and hypersensitivity
    •
  • Speculative: Cumulative toxicity from high-dose, long-term stacking
    •

Monitoring

Marker Target Why
ALT / AST (liver enzymes) ALT ~10–26 U/L; AST ~10–26 U/L Detect drug-related liver injury
Total bilirubin 0.3–1.0 mg/dL Assess overall liver clearance
Complete blood count (CBC) Within age/sex norms Track marrow effects and cancer-related changes
Comprehensive metabolic panel (CMP) Within age/sex norms Monitor kidney, electrolytes, glucose, liver together
Cancer-specific markers / imaging Per tumor type Track the actual cancer, the only true efficacy measure

Cadence: Baseline before starting; recheck liver function approximately every 4–8 weeks during prolonged use; cancer imaging and markers per standard oncology schedule.

Qualitative Assessment

  • Energy levels and fatigue
  • Appetite and weight stability
  • New or worsening neurological symptoms (dizziness, confusion, tremor, visual changes)
  • General well-being and tolerability of the regimen
  • Pain or other tumor-related symptoms
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.